{
    "clinical_study": {
        "@rank": "9763", 
        "arm_group": {
            "arm_group_label": "BGJ398", 
            "arm_group_type": "Experimental", 
            "description": "Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate safety and tolerability to determine the Maximum tolerated dose\n      (MTD) and/or Recommended dose (RD)."
        }, 
        "brief_title": "A Phase I Study of Oral BGJ398 in Asian Patients", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Tumor With Alterations of the FGF-R", 
        "detailed_description": {
            "textblock": "This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398,\n      administered on a continuous once and/or twice daily schedule."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with advanced solid tumors with FGF-R alteration\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Patients with untreated and/or symptomatic metastatic Central Nerve System (CNS)\n             disease\n\n          -  Pregnant or nursing (lactating) women\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697605", 
            "org_study_id": "CBGJ398X1101"
        }, 
        "intervention": {
            "arm_group_label": "BGJ398", 
            "intervention_name": "BGJ398", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Phase I, open-label, dose escalation, BGJ398, Japanese, Asian, FGF-R", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-city", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "466-8560"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobe-city", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "650-0017"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunto-gun", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "411-8777"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximum tolerated dose (MTD) and/or Recommended dose (RD) of single agent oral BGJ398", 
            "measure": "Incidence rate and category of dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "First cycle of 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697605"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the safety and tolerability of oral BGJ398", 
                "measure": "Frequency of all Adverse Events (AEs) and Serious Advers Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From within 21 days of first treatment to 28 days after treatment discontinuation"
            }, 
            {
                "description": "hematology and chemistry values", 
                "measure": "Changes in hematology and chemistry values", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 28 days after treatment discontinuation"
            }, 
            {
                "measure": "Assessments of physical examinations, vital signs and electrocardiograms (ECGs)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of treatment, an expected average of 24 weeks."
            }, 
            {
                "description": "To determine the pharmacokinetic (PK) profiles (Cmax, AUC, Tmax, T1/2, etc) of oral BGJ398 including known pharmacologically active metabolites", 
                "measure": "Time vs. concentration profiles", 
                "safety_issue": "No", 
                "time_frame": "1 to 10 time points (0, 0.25, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose) up to 24 weeks"
            }, 
            {
                "description": "Assessed based on RECIST version 1.1", 
                "measure": "Preliminary anti-tumor activity", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of treatment, an expected average of 24 weeks."
            }, 
            {
                "description": "Assessed by investigator per RECIST version 1.1. BOR is the best response recorded until disease progression.", 
                "measure": "Best overall response (BOR)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of treatment, an expected average of 24 weeks."
            }, 
            {
                "description": "Assessed by investigator per RECIST version 1.1. ORR is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of treatment, an expected average of 24 weeks."
            }, 
            {
                "description": "PFS is defined as the times from the date of first dose of BGJ398 to the date of the first documented disease progression, date of death due to any cause or until a new anticancer therapy is initiated, whichever occurs first.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From date of end of treatment until the date of progression, or date of death, or starting date of a new anticancer therapy, assessed up to 100 months."
            }, 
            {
                "description": "To characterize the safety and tolerability of oral BGJ398", 
                "measure": "Duration of all Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From within 21 days of first treatment to 28 days after treatment discontinuation"
            }, 
            {
                "description": "To characterize the safety and tolerability of oral BGJ398", 
                "measure": "Duration of Serious Advers Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From within 21 days of first treatment to 28 days after treatment discontinuation"
            }, 
            {
                "description": "To characterize the safety and tolerability of oral BGJ398", 
                "measure": "Severity of all Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From within 21 days of first treatment to 28 days after treatment discontinuation"
            }, 
            {
                "description": "To characterize the safety and tolerability of oral BGJ398", 
                "measure": "Severity of all Serious Advers Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From within 21 days of first treatment to 28 days after treatment discontinuation"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}